EUVIMEDAtrasti EUVIMED
Klinische StudieOpen access · CC BY-NC 4.0

Clinical Trial: Effectiveness and Safety of a Novel Anal Insert Device for Treatment of Faecal Incontinence

Klinische Studie: Wirksamkeit und Sicherheit eines neuartigen Anal-Inserts zur Behandlung der Stuhlinkontinenz

Adil E Bharucha, Ramesh Lamichhane, Joel G Fletcher, Nicholas R Oblizajek iD, Misha Gautam iD, Kent R Bailey, Lawrence A Szarka

Alimentary Pharmacology & Therapeutics · 2026-09 · 64 (5) · 603-614

DOI: 10.1111/apt.70831 ↗

Auf einen Blick

Bei Patient:innen mit medikamentös bzw. konservativ refraktärer Stuhlinkontinenz war StaySure mit weniger Inkontinenzepisoden und besserer Lebensqualität verbunden. Schwere behandlungsbedingte Nebenwirkungen traten nicht auf.

Fragestellung

Wie wirksam und sicher ist das neue Anal-Insert StaySure bei Patient:innen mit Stuhlinkontinenz?

Methode

Patient:innen mit FI seit ≥ 6 Monaten und ≥ 4 moderaten oder großen Episoden in 4 Wochen; 2–4 Wochen Anpassungsphase und 4 Wochen Behandlung. Primärer Endpunkt: ≥ 50 % weniger FI-Häufigkeit.

Ergebnisse

Von 124 eingeschlossenen Patient:innen gingen 98, 71 und 61 durch Baseline-, Anpassungs- und Behandlungsphase. In der ITT-Kohorte von 59 sank die Zahl der Tage mit FI von 13,2 (7,0) auf 6,3 (6,9) und die Wochenepisoden von 5,4 (6,9) auf 2,1 (5,1) (69 %; p < 0,001).

Schlussfolgerung der Autor:innen

StaySure war sicher, gut verträglich und wirksam zur Reduktion von FI bei Patient:innen mit moderaten bis schweren Beschwerden trotz konservativer Therapien.

Kernaussagen

  • Primärer Endpunkt bei 76,3 % erreicht
  • FI-Wochenepisoden: 5,4 auf 2,1
  • Keine behandlungsbedingten schweren unerwünschten Ereignisse

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Klinische Studie in Alimentary Pharmacology & Therapeutics, published online on 2026-07-21. Written by Adil E Bharucha and 6 co-authors. Institution: Division of Gastroenterology and Hepatology (Bharucha, Oblizajek, and Szarka), Department of Radiology (Fletcher), and Division of Clinical Trials an…. Major MEDLINE topics: Anal Canal, Fecal Incontinence. Cited 5 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: minnesota medical technologies.

Auf einen BlickSantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Background

Treatment options for medically‐refractory faecal incontinence ( FI )—including anorectal biofeedback, dextranomer injection, and sacral nerve stimulation—are limited and outcomes are often suboptimal. Anal or vaginal insert devices are infrequently used.

Aims

We evaluated the safety and effectiveness of a new anal insert device (StaySure) in patients with FI.

Methods

Patients with FI for ≥ 6 months and ≥ 4 moderate or large FI episodes during a 4‐week baseline entered a 2–4 week fitting/run‐in period to individualise device size (10 or 13 mm) followed by a 4‐week treatment period. Outcomes included effectiveness, safety, and quality of life (QoL). The primary outcome was the proportion achieving a ≥ 50% reduction in FI frequency.

Results

Of 124 enrolled patients, 98, 71, and 61 progressed through the baseline, fitting/run‐in, and treatment phases respectively, with few exclusions due to device intolerance. In the intent‐to‐treat cohort of 59 participants (93% women), mean ( SD ) number of days with FI declined from 13.2 (7.0) to 6.3 (6.9), and FI weekly episodes declined from 5.4 (6.9) to 2.1 (5.1) (69% reduction; p < 0.001) with similar results for both device sizes. The primary endpoint was achieved in 76.3% of participants; 54.2% achieved ≥ 75% reduction. The FIQoL overall score increased from a mean ( SD ) of 1.9 (0.6) to 2.3 (0.6) ( p < 0.001), indicating improved QoL . Improvements in FI frequency, FIQoL exceeded minimal clinically important difference thresholds, confirming clear clinical benefit. No treatment‐related serious adverse events were reported.

Conclusions

The StaySure anal insert device is safe, well tolerated, and effective in reducing FI in patients with moderate to severe symptoms refractory to conservative therapies. Trial Registration ClinicalTrials.gov identifier: NCT03898778

Subjects

MeSH terms (MEDLINE)

Anal CanalFecal IncontinenceAdultAgedFemaleHumansMaleMiddle AgedQuality of LifeTreatment Outcome

Author keywords

accidental bowel leakageanal barrier deviceanal incontinencefaecal incontinencequality of life

Authors and institutions

  • Division of Gastroenterology and Hepatology (Bharucha, Oblizajek, and Szarka), Department of Radiology (Fletcher), and Division of Clinical Trials and Biostatistics (Bailey), Mayo Clinic, Mayo Clinic School of Graduate…

ORCID profiles: Nicholas R Oblizajek, Misha Gautam

Funding

  • minnesota medical technologies

Cite

APA

Bharucha, A. E., Lamichhane, R., Fletcher, J. G., Oblizajek, N. R., Gautam, M., Bailey, K. R., & Szarka, L. A. (2026). Clinical Trial: Effectiveness and Safety of a Novel Anal Insert Device for Treatment of Faecal Incontinence. Alimentary Pharmacology & Therapeutics, 64(5), 603-614. https://doi.org/10.1111/apt.70831

Vancouver

Bharucha AE, Lamichhane R, Fletcher JG, Oblizajek NR, Gautam M, Bailey KR, et al. Clinical Trial: Effectiveness and Safety of a Novel Anal Insert Device for Treatment of Faecal Incontinence. Alimentary Pharmacology & Therapeutics. 2026;64(5):603-614. doi:10.1111/apt.70831

BibTeX
@article{Bharucha2026,
  author = {Bharucha, Adil E and Lamichhane, Ramesh and Fletcher, Joel G and Oblizajek, Nicholas R and Gautam, Misha and Bailey, Kent R and Szarka, Lawrence A},
  title = {Clinical Trial: Effectiveness and Safety of a Novel Anal Insert Device for Treatment of Faecal Incontinence},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {64},
  number = {5},
  pages = {603--614},
  doi = {10.1111/apt.70831}
}
Start for free →